Gilead Sciences (GILD) Misses Q1 EPS by 288c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
- Applied Digital (APLD) Tops Q1 EPS by 26c, Beats on Revenue
Gilead Sciences (GILD) PT Lowered to $76 at Barclays
April 29, 2024 5:23 AM EDTBarclays analyst Carter Gould lowered the price target on Gilead Sciences (NASDAQ: GILD) to $76.00 (from $80.00) while maintaining a Equalweight rating.
The analyst comments "'25 HIV zero-growth messaging, puts onus on cell therapy and seladelpar launch to deliver overall top-line growth. Focus... More



